Technology | August 06, 2013

CIRS Introduces New End-to-End QA Tool for Stereotactic Radiosurgery Systems

CIRS announces Stereotactic End-to-End Verification Phantom at AAPM Annual Meeting

Cirus Inc. STEEV QA System Radiosurgery Radiation Therapy Phantom

August 6, 2013 — CIRS will introduce the Stereotactic End-to-End Verification Phantom (STEEV) at the 55th Annual AAPM Meeting and Exhibition on August 4 to 8 in Indianapolis.

CIRS Stereotactic End-to-End Verification Phantom (STEEV™) shown with 12 optional inserts.

STEEV is a QA tool for evaluating stereotactic radiosurgery (SRS) system performance during commissioning and daily systems checks. To facilitate patient QA, STEEV serves as a surrogate patient to assess every step of the treatment process- from immobilization and multi-modality imaging (computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)) to thorough treatment plan verification. STEEV's anthropomorphic, tissue-equivalent design makes it the only phantom to account for the challenging effects of tissue heterogeneity.

SRS is a non-invasive procedure that focuses high doses of radiation to destroy tumor volumes in small areas of the body. The procedure necessitates a high degree of accuracy in target localization and dose delivery, because small errors can result in significant under treatment of portions of the tumor volume or overdose of nearby healthy tissues. By providing challenging system checks, STEEV helps to identify system errors and ultimately leads to better patient outcomes- a key component to CIRS' company values.

The introduction of STEEV compliments CIRS' existing suite of site-specific end-to-end QA phantoms, including the Dynamic Thorax Phantom, Dynamic Pelvis Phantom and SBRT Thorax Phantom.

For more information: www.cirsinc.com 

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init